CN108192972B - 用于乳腺癌转移的诊断、预后和治疗的方法 - Google Patents

用于乳腺癌转移的诊断、预后和治疗的方法 Download PDF

Info

Publication number
CN108192972B
CN108192972B CN201810147703.5A CN201810147703A CN108192972B CN 108192972 B CN108192972 B CN 108192972B CN 201810147703 A CN201810147703 A CN 201810147703A CN 108192972 B CN108192972 B CN 108192972B
Authority
CN
China
Prior art keywords
maf
gene
expression level
amplification
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810147703.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108192972A (zh
Inventor
R·戈米斯卡布雷
M·塔拉戈纳苏涅尔
A·阿纳尔埃斯塔佩
M·帕夫洛维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut de Recerca Biomedica IRB
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut de Recerca Biomedica IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES201031478A external-priority patent/ES2379918B1/es
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut de Recerca Biomedica IRB filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Publication of CN108192972A publication Critical patent/CN108192972A/zh
Application granted granted Critical
Publication of CN108192972B publication Critical patent/CN108192972B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
CN201810147703.5A 2010-10-06 2011-10-05 用于乳腺癌转移的诊断、预后和治疗的方法 Active CN108192972B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ESP201031478 2010-10-06
ES201031478A ES2379918B1 (es) 2010-10-06 2010-10-06 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama.
ES201131073 2011-06-27
ESP201131073 2011-06-27
PCT/ES2011/070693 WO2012045905A2 (es) 2010-10-06 2011-10-05 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
CN201180058347.6A CN103339265B (zh) 2010-10-06 2011-10-05 用于乳腺癌转移的诊断、预后和治疗的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180058347.6A Division CN103339265B (zh) 2010-10-06 2011-10-05 用于乳腺癌转移的诊断、预后和治疗的方法

Publications (2)

Publication Number Publication Date
CN108192972A CN108192972A (zh) 2018-06-22
CN108192972B true CN108192972B (zh) 2022-09-09

Family

ID=45099129

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180058347.6A Active CN103339265B (zh) 2010-10-06 2011-10-05 用于乳腺癌转移的诊断、预后和治疗的方法
CN201810147703.5A Active CN108192972B (zh) 2010-10-06 2011-10-05 用于乳腺癌转移的诊断、预后和治疗的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201180058347.6A Active CN103339265B (zh) 2010-10-06 2011-10-05 用于乳腺癌转移的诊断、预后和治疗的方法

Country Status (13)

Country Link
US (3) US10047398B2 (enExample)
EP (3) EP2626431B1 (enExample)
JP (5) JP6159254B2 (enExample)
KR (2) KR102240323B1 (enExample)
CN (2) CN103339265B (enExample)
AR (1) AR083357A1 (enExample)
AU (4) AU2011311452B2 (enExample)
BR (1) BR112013008505B1 (enExample)
CA (1) CA2813674C (enExample)
DK (2) DK2626431T3 (enExample)
ES (3) ES2721639T3 (enExample)
MX (2) MX382266B (enExample)
WO (1) WO2012045905A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011311452B2 (en) 2010-10-06 2016-09-01 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
CA2875918A1 (en) 2012-06-06 2013-12-12 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
HK1213946A1 (zh) * 2012-10-12 2016-07-15 Inbiomotion S.L. 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014184679A2 (en) * 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
AU2014229505B2 (en) * 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
EP2975138A2 (en) * 2013-03-15 2016-01-20 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis, prognosis and treatment of cancer metastasis
ES2727904T3 (es) * 2013-10-09 2019-10-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastatizante del hueso que se origina a partir de cáncer de mama
EP2933639A1 (en) * 2014-04-16 2015-10-21 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts S100p and Hyaluronic acid as biomarkers for metastatic breast cancer
CN104398506A (zh) * 2014-12-09 2015-03-11 厦门大学 雷奈酸锶在制备预防和治疗腺癌药物中的新用途
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
WO2017203468A1 (en) * 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
KR101896558B1 (ko) 2016-11-21 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
CN107699619B (zh) * 2017-11-17 2019-02-22 柳超 lncRNA组合物及制备诊断预示Luminal B型乳腺癌骨转移基因诊断试剂盒的用途
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
JP2023079997A (ja) 2021-11-29 2023-06-08 東洋インキＳｃホールディングス株式会社 活性エネルギー線硬化型インクジェットインキ及び印刷物
CN114574577A (zh) * 2022-01-04 2022-06-03 中山大学孙逸仙纪念医院 Mettl16基因及其用途
CN119614707A (zh) * 2025-01-13 2025-03-14 中山大学 ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
WO2009045115A1 (en) * 2007-10-05 2009-04-09 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1997038117A1 (en) 1996-04-05 1997-10-16 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
EP0946725B1 (en) 1996-12-23 2011-01-26 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
EA200100972A1 (ru) 1999-03-15 2002-02-28 Аксис Фармасьютикалз, Инк. Новые соединения и композиции как ингибиторы протеаз
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
AU779855B2 (en) 2000-01-06 2005-02-17 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
PL222211B1 (pl) 2001-06-26 2016-07-29 Amgen Fremont Inc Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
KR20040058277A (ko) 2001-11-13 2004-07-03 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 캘리브레이션 유도 방법, 이미지 처리 방법 및 이미지시스템
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
EP1668354A2 (en) 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Method of diagnosing breast cancer
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
JP2007527247A (ja) 2004-03-05 2007-09-27 ロゼッタ インファーマティクス エルエルシー 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
EP3211086B1 (en) 2005-09-20 2021-06-09 Menarini Silicon Biosystems S.p.A. Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes
US20080219996A1 (en) 2005-09-26 2008-09-11 Thea Kalebic Molecular Markers Associated with Bone Metastasis
WO2007069090A2 (en) 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2008145125A1 (en) 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
US20110123617A1 (en) 2007-10-18 2011-05-26 University Health Network Clioquinol for the treatment of hematological malignancies
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
WO2009146546A1 (en) 2008-06-06 2009-12-10 University Health Network 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
ES2338843B1 (es) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
US8728738B2 (en) 2008-07-02 2014-05-20 Assistance Publique-Hopitaux De Paris Method for predicting clinical outcome of patients with non-small cell lung carcinoma
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
SG176073A1 (en) 2009-05-29 2011-12-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
WO2011017687A1 (en) 2009-08-06 2011-02-10 Ray Partha S Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
AU2011311452B2 (en) 2010-10-06 2016-09-01 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
CA2826657A1 (en) 2011-02-04 2012-08-09 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EP2685988A4 (en) 2011-03-15 2014-08-20 Univ North Carolina Methods of treating breast cancer with anthracycline therapy
EP2780469A1 (en) 2011-11-18 2014-09-24 Vanderbilt University Markers of triple-negative breast cancer and uses thereof
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
CA2875918A1 (en) 2012-06-06 2013-12-12 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
HK1213946A1 (zh) 2012-10-12 2016-07-15 Inbiomotion S.L. 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
EP2975138A2 (en) 2013-03-15 2016-01-20 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis, prognosis and treatment of cancer metastasis
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
ES2727904T3 (es) 2013-10-09 2019-10-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastatizante del hueso que se origina a partir de cáncer de mama
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
WO2017203468A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
WO2009045115A1 (en) * 2007-10-05 2009-04-09 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Breast cancer markers;Vincenzo Giancotti等;《Cancer Lett》;20061118;第243卷(第2期);第145-159页 *
The Evolving Role of Bone-Conserving Therapy in Patients With Breast Cancer;Adam M Brufsky等;《Semin Oncol》;20100630;第37卷(第S1期);摘要，第S14页左栏第1、2段，第S15页左栏第1段 *
趋化因子受体CCR7促进乳腺癌细胞的趋化与侵袭;马飞等;《第四军医大学学报》;20041231;第25卷(第20期);第1883-1886页 *

Also Published As

Publication number Publication date
AR083357A1 (es) 2013-02-21
CN103339265A (zh) 2013-10-02
JP2021192636A (ja) 2021-12-23
AU2021203599B2 (en) 2024-10-10
US20140057796A1 (en) 2014-02-27
KR102240323B1 (ko) 2021-04-14
EP2626431A2 (en) 2013-08-14
US12312642B2 (en) 2025-05-27
EP3091085A1 (en) 2016-11-09
US11072831B2 (en) 2021-07-27
DK3091085T3 (da) 2019-05-06
MX382266B (es) 2025-03-13
US20220049316A1 (en) 2022-02-17
KR20140071946A (ko) 2014-06-12
DK2626431T3 (en) 2015-12-21
JP2017104115A (ja) 2017-06-15
JP6159254B2 (ja) 2017-07-12
EP3091085B1 (en) 2019-02-27
AU2019201493B2 (en) 2021-03-11
JP6946385B2 (ja) 2021-10-06
JP2013541339A (ja) 2013-11-14
JP6571698B2 (ja) 2019-09-04
CN103339265B (zh) 2018-03-30
BR112013008505A2 (pt) 2016-07-05
MX2013003880A (es) 2013-12-02
AU2021203599A1 (en) 2021-07-01
CN108192972A (zh) 2018-06-22
AU2016266009B2 (en) 2018-12-06
EP3517630B1 (en) 2022-01-19
ES2721639T3 (es) 2019-08-02
AU2019201493A1 (en) 2019-03-28
WO2012045905A2 (es) 2012-04-12
AU2016266009A1 (en) 2016-12-15
ES2911505T3 (es) 2022-05-19
KR101944555B1 (ko) 2019-02-01
EP3517630A1 (en) 2019-07-31
AU2011311452A1 (en) 2013-05-09
CA2813674C (en) 2020-11-24
BR112013008505B1 (pt) 2023-01-24
MX344315B (es) 2016-12-13
KR20190009835A (ko) 2019-01-29
ES2562274T3 (es) 2016-03-03
EP2626431B1 (en) 2015-09-16
WO2012045905A3 (es) 2012-06-21
US20190169693A1 (en) 2019-06-06
AU2011311452B2 (en) 2016-09-01
CA2813674A1 (en) 2012-04-12
HK1187377A1 (en) 2014-04-04
JP2019195340A (ja) 2019-11-14
JP2018099132A (ja) 2018-06-28
US10047398B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
CN108192972B (zh) 用于乳腺癌转移的诊断、预后和治疗的方法
KR102252332B1 (ko) 암 전이의 예후 및 치료 방법
AU2014333513B2 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
KR101872965B1 (ko) Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
JP2016518815A (ja) 転移性がんの診断、予後、および処置の方法
HK40011542B (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
HK40011542A (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
HK1229858B (en) Method of designing a therapy for breast cancer metastasis
HK1229858A1 (en) Method of designing a therapy for breast cancer metastasis
HK1229858A (en) Method of designing a therapy for breast cancer metastasis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant